Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tralokinumab Safety in Japanese Asthma Patients
NCT02902809Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Nov 2016
- Primary completion
- Jan 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of tralokinumab in asthma, sponsored by AstraZeneca. Started Nov 2016; status: terminated.
02
Drugs
tralokinumab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02902809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02902809.